Last reviewed · How we verify
SB756050
At a glance
| Generic name | SB756050 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050 (PHASE1)
- A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB756050 CI brief — competitive landscape report
- SB756050 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI